CYTEGRITY
LIVE

Serial Number

98232780

Owner

CSL Behring Gene Therapy, Inc.

Attorney

Scott D. Woldow

Filing Date

Oct 20, 2023

Add to watchlist:

No watchlists yet
View on USPTO

CYTEGRITY Trademark

Serial Number: 98232780

CYTEGRITY is a trademark filed by CSL Behring Gene Therapy, Inc. on October 20, 2023. The trademark is classified under Class 40 (Treatment & Processing), Class 42 (Computer & Scientific), Class 45 (Legal & Security Services), Class 35 (Advertising & Business). The application is currently pending registration.

Owner Contact Info

CSL Behring Gene Therapy, Inc.

Suite 650
Pasadena, CA 91101

Entity Type: 03

Trademark Details

Filing Date

October 20, 2023

Registration Date

Not Registered

Published for Opposition

May 13, 2025

Goods & Services

Regulatory compliance consulting in the field of clinical manufacturing

Scientific and pharmaceutical research and development; medical research; biological research; Scientific laboratory services in in the field of viral vectors and gene therapy vectors; Scientific, pharmaceutical, and medical research in the field of bioproduction, regulatory pathway services, accessory proteins and alternative envelope proteins; Scientific research consulting in the field of clinical manufacturing

Biomanufacturing for others, namely, manufacturing of pharmaceuticals and of viral vectors and gene therapy vectors using biological organisms or viruses in the manufacturing process; custom manufacturing services of ex vivo, lentiviral stable cell lines; custom manufacturing services of lentiviral vectors by transient transfection; Biomanufacturing for others, namely, manufacturing of viral vectors and gene therapy vectors using biological organisms or viruses in the manufacturing process; biomanufacturing for others, namely, manufacturing of cell lines and cells using biological organisms or viruses in the manufacturing process; biomanufacturing for others, namely, manufacturing of biological preparations for use in industry and science, and cell cultures for medical purposes using biological organisms or viruses in the manufacturing process; Biomanufacturing process consulting

Business consultation in the field of business process improvement for clinical manufacturing

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Jun 8, 2026 EXRA
SOU EXTENSION 2 GRANTED
Jun 8, 2026 EX2G
SOU EXTENSION 2 FILED
Jun 8, 2026 EXT2
SOU TEAS EXTENSION RECEIVED
Jun 8, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Dec 8, 2025 EXRA
SOU EXTENSION 1 GRANTED
Dec 8, 2025 EX1G
SOU EXTENSION 1 FILED
Dec 8, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Dec 8, 2025 EEXT
ASSIGNED TO EXAMINER
Aug 25, 2025 DOCK
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Jul 8, 2025 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
May 13, 2025 NPUB
PUBLISHED FOR OPPOSITION
May 13, 2025 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
May 7, 2025 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Apr 15, 2025 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
Apr 14, 2025 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Apr 14, 2025 CRFA
TEAS REQUEST FOR RECONSIDERATION RECEIVED
Apr 14, 2025 ERFR
NOTIFICATION OF FINAL REFUSAL EMAILED
Jan 14, 2025 GNFN
FINAL REFUSAL E-MAILED
Jan 14, 2025 GNFR
FINAL REFUSAL WRITTEN
Jan 14, 2025 CNFR
TEAS/EMAIL CORRESPONDENCE ENTERED
Dec 11, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Dec 11, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Dec 11, 2024 TROA
APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Sep 11, 2024 XELG
APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Sep 11, 2024 XELR
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jun 13, 2024 GNRN
NON-FINAL ACTION E-MAILED
Jun 13, 2024 GNRT
NON-FINAL ACTION WRITTEN
Jun 13, 2024 CNRT
ASSIGNED TO EXAMINER
Jun 5, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Oct 25, 2023 NWOS
NEW APPLICATION ENTERED
Oct 24, 2023 NWAP